Objectives/Hypothesis: The prevalence of human papillomavirus (HPV) in a clinical series of 162 patients with oral squamous cell carcinoma (OSCC) was studied. Furthermore, we analyzed the correlation between the immunohistochemical expression of p16, p53, epidermal growth factor receptor (EGFR), and HPV status to predict survival in OSCC patients.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common malignancy diagnosed worldwide and involves the oral cavity, larynx, hypopharynx, and oropharynx. HNSCC is characterized by different incidences and mortalities around the world, with higher mortality rates in Eastern Europe. 1 In 2008, there were 634,760 new cases of HNSCC diagnosed worldwide, including 263,020 cases of oral squamous cell carcinoma (OSCC), which represented 41% of all new HNSCC diagnoses. 2 Tobacco use and alcohol consumption are well-established risk factors for the development of HNSCC; however, a portion of HNSCC patients (15%-20%) develop tumors, even in the absence of exposure to these agents. 3 Moreover, Sturgis and Cinciripini 4 reported that the overall incidence of HNSCC has declined in the United States in the past 20 years, which has been attributed to a decrease in smoking. Nevertheless, the study also demonstrated an increase in the frequency of tongue and pharyngeal cancers. These findings suggest the importance of other risk factors, such as human papillomavirus (HPV), in the development of oropharyngeal and oral carcinomas.
The capacity of HPV to transform epithelial cells is divided into high-risk (hr) and low-risk (lr) HPV: a benign proliferation is associated with the lr HPV type and malignancy is associated with the hr HPV type. The following were considered hr HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59 , and 66. The HPV types responsible for lr infections are 6, 11, 40, 42, 43, 44, 54, 61, 72, 73 , and 81.
The significance of hr HPV infection and its relationship to patient prognosis remains an important matter of debate, especially when considering the contradictory results presented in different published studies. [5] [6] [7] Generally, the majority of authors report a favorable prognosis in patients with HPV-positive HNSCC. 6, [8] [9] [10] However, other studies have suggested that the hr HPVþ subgroup is at a greater risk of recurrence or development of a second primary tumor. 7, 11 Moreover, some authors did not find a significant correlation between hr HPV positivity and clinical outcome. [12] [13] [14] [15] Molecular studies have demonstrated that the E6 and E7 oncoproteins play crucial roles in malignant transformation. 16 The E6 oncoprotein promotes degradation of p53 via the ubiquitin pathway, 17 and the E7 oncoprotein has a strong affinity for pRB and promotes its degradation. 18, 19 The E5 oncoprotein has been suggested to play an early role in the transformation of HPV-infected cells via an interaction with epidermal growth factor receptor (EGFR). 18, 20 The p16 protein also functions as a tumor suppressor by binding to the cyclin D1 CDK4/CDK6 complex and preventing the phosphorylation of the Rb protein. pRb downregulation subsequently results in p16 upregulation. 21 The aim of this study was to assess the presence of HPV DNA using GP5þ/GP6þ consensus polymerase chain reaction (PCR), genotyping with type-specific E6/ E7 PCR primers for 18 HPV types, and in situ hybridization (ISH) in a series of 162 patients with OSCC. The study patients were characterized during long-term follow-up. In addition, we analyzed the immunohistochemical expression of p16, p53, and EGFR and their correlation with HPV DNA in an effort to predict survival in OSCC patients.
MATERIALS AND METHODS

Histopathologic and Clinical Data
Formalin-fixed, paraffin-embedded OSCC specimens were obtained from 162 patients (130 males, 32 females) who underwent radical curative surgery between January 1994 and December 2008 at the Saint-Pieter Hospital (Brussels), R.H.M.S. (Baudour), and the Erasme Hospital (Brussels). The clinical data collected from this series of 162 OSCC patients are described in Table I . This prospective and retrospective study was approved by the Saint-Pieter Institutional Review Board (AK/09-09-47/3805AD).
HPV Detection and Typing
HPV detection and typing from paraffin-embedded tissues were performed as described in our previous work. 5 DNA extraction was performed following the protocol from the QIAamp DNA Mini Kit (Qiagen, Benelux, Belgium). 19 HPV detection was performed using PCR with GP5þ/GP6þ primers. 5 All DNA extracts were analyzed for the presence of 18 different HPV genotypes using a TaqMan-based real-time quantitative PCR (qPCR) targeting type-specific sequences of the following viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58 E6, 59 E7, 66 E6, 67 L1, and 68 E7. 22 Real-time qPCR for the detection of b-globin was performed in each PCR assay to verify the quality of the DNA in the samples and to measure the amount of input DNA. 23, 24 HPV ISH ISH was performed using the INFORM HPV III Family 16 probe (high-risk ISH probe) (Ventana Medical Systems Inc., Tucson, AZ). The staining protocol was performed using the BenchMark automated stainer (Ventana) according to the manufacturer's instructions. Randomly selected full tissue sections corresponding to 20 hr HPVþ OSCC samples and 20 HPVÀ OSCC samples were analyzed using the high-risk ISH assay.
Immunohistochemistry
The p16, p53, and EGFR immunohistochemistry were performed as described previously. 5, 25 The tumors were classified based on the expression of p16, p53, and EGFR. Positive expression was defined as weak to strong immunostaining with a labeling index between 5% and 95%, while negative expression was defined as no staining. The labeling index corresponded to the percentage of immunopositive cells.
Data Analysis
Categorical data from independent groups were compared using the v 2 test or Fisher exact test, as appropriate. Diseasefree and survival data were measured in terms of months from the date of diagnosis until disease recurrence or death or until the date at which the patient was last known to be alive. Standard survival time analyses were performed using Kaplan-Meier curves. Gehan's generalized Wilcoxon and log-rank tests were used to determine the significance of the difference between two (or more) curves. A standard Cox regression analysis was used to fit disease-free data in the explanatory models generated based on the variables analyzed in the study (i.e., HPV status, TNM, node status, risk factors, differentiation, and recurrence). Statistical analyses were performed using the Statistica software package (Statsoft, Tulsa, OK).
RESULTS
HPV Status in OSCC Specimens
Six of the 162 specimens had insufficient tissue quantities for DNA extraction after pathologic evaluation; therefore, they were excluded from further analyses. Of the remaining 156 cases, nine were excluded because b-globin could not be amplified ( Fig.  1 ). Based on the 147 OSCC tumor specimens examined, we identified 65 patients (44%) who tested positive for the following hr HPV types: HPV 16 (61 cases), 45 (1 case), 53 (1 case), 58 (1 case), 59 (3 cases), 66 (1 case), and 67 (1 case). In three specimens, multiple hr HPV serotypes were detected. Among the 65 hr HPVþ tumors, 53 specimens (53 of 147 cases; 36%) were positive in the GP5þ/GP6þ PCR and the qPCR. However, 12 tumors (12 of 147 cases; 8%) were GP5þ/GP6þ negative were positive using the GP5þ/GP6þ PCR and were considered to be infected with lr HPV (Fig. 1) . A total of 44 OSCC samples (30%) tested negative in the GP5þ/GP6þ and type-specific HPV PCR analyses and were therefore considered HPV negative.
Validation of HPV DNA Detection Using ISH
To validate our PCR and qPCR results, we performed ISH on 40 samples from the 147 OSCC specimens (20 hr HPVþ specimens and 20 HPVÀ specimens). 
Correlation Between HPV DNA and Clinical Data in Our Series of OSCC Samples
The HPV-positive clinical series presented in this study was particularly heterogeneous. It was composed of men (n ¼ 49) and women (n ¼ 16), 23 to 81 years of age, presenting with poorly, moderately, or well-differentiated tumors (Table I) . Importantly, many of the patients were active smokers (n ¼ 37) or drinkers (n ¼ 32), whereas another subset of patients was comprised of former smokers (n ¼ 15) or drinkers (n ¼ 12) (Table I) . Nonsmoking (n ¼ 7) and nondrinking (n ¼ 15) patients constituted the smallest population of our clinical series. However, after statistical analyses, none of these clinical data could be correlated with HPV status (Table I) .
Prognostic Value of hr HPV DNA in Our Series of OSCC Samples
High-risk HPV positivity was associated with shorter disease-free survival in our series of 147 OSCC patients. The 5-year disease-free survival was 76% for patients with HPVÀ tumors versus 40% for patients with HPVþ tumors (log rank test, P ¼ .007) (Fig. 3A) . Furthermore, the 5-year disease-free survival was 48% for patients with lr HPVþ tumors versus 37% for patients with hr HPVþ tumors (log rank test, P ¼ .015) (Fig. 3B) . These data suggest that HPV infection was significantly associated with a worse prognosis. Moreover, the Cox multivariate analyses combining the HPV status with the clinical variables (TNM staging and node status) demonstrated that only HPV status had an independent impact on patient prognosis (P ¼ .01; hazard ratio ¼ 2.81). An analysis of viral loads in infected patients did not show any statistically significant relationship between TNM staging or risk of recurrence (data not shown).
Prognostic Value of EGFR, p53, and p16 Expression
Due to insufficient biopsy material, only 155 cases were analyzed for EGFR expression, 158 for p53 expression, and 161 for p16 expression.
EGFR expression. Figure 4A shows the typical EGFR immunostaining pattern, with expression local-ized to the tumor cell plasma membrane. Of the 155 HNSCC specimens, 96% (149 of 155 cases) were EGFRþ. Identical rates of EGFR positivity were observed in the hr HPVþ tumor group (92% were EGFRþ) and in the HPVÀ and lr HPVþ tumor groups (92% were EGFRþ). In both populations, EGFR immunostaining was strong, and the percentage of EGFRþ tumor cells per positive case reached 90%. A comparison of the disease-free survival curves based on EGFR immunohistochemical staining did not show any statistically significant differences (Fig. 4B) .
p16 expression. We detected p16 expression via immunohistochemistry in 53% (85 of 161 cases) of the OSCC samples. In the lr HPV/HPVÀ groups, 44% of specimens (36 of 82 cases) were p16þ, whereas this percentage increased to 65% (42 of 65 cases) in the hr HPVþ group. As shown in Figure 4C , p16 expression was weak and predominantly cytoplasmic. The mean percentage of p16 immunopositive cells was 25%. Statistical analyses did not show any impact of p16 expression on disease-free survival (Fig. 4D ).
p53 expression. Immunostaining of p53 was detected in 51% (81 of 158 cases) of the OSCC samples. A total of 57% (47 of 82 cases) of the samples from the lr HPV/HPVÀ groups were p53þ, and only 41.5% (27 of 65 cases) of the hr HPVþ subpopulation were p53þ. As shown in Figure 4E , p53 displayed a moderate nuclear expression pattern with an average of 41% of tumor cells. Furthermore, there was no significant difference between the four disease-free survival curves based on p53 immunohistochemical staining (Fig. 4F) .
DISCUSSION
In 1983, Syrj€ anen et al. 26 first suggested that HPV might be involved in OSCC carcinogenesis. Although many studies have aimed to characterize the effects of HPV infection on oral malignancies, its contribution to the development and progression of OSCC currently remains unclear. Therefore, we investigated whether a correlation exists between HPV infection, patient prognosis, tumor suppressor genes, and EGFR expression in a large series of OSCC patients with a history of tobacco and alcohol use. In our study, the prevalence of HPV infection reached 70%, with 44% of samples containing hr HPV DNA and 26% of samples containing lr HPV DNA. The implication of HPV-6 and -11 in the development of recurrent respiratory papillomatosis (RRP) is clearly established. Although the RRP is a benign disease, the recurrent nature of the lesions in the airways requires frequent surgical procedures and causes significant morbidity and occasional mortality secondary to airway obstruction. 27 For this reason, it is important to distinguish a lesion infected by a lr HPV from an HPVnegative lesion. Our results are in accordance with several reports indicating that HPV DNA can be detected in greater than 40% of OSCC tumors. [28] [29] [30] However, several authors have reported a prevalence of 20% to 30%. 13, 31, 32 According to a meta-analysis performed by Kreimer et al., these variations in prevalence may be due to several factors such as the method of sample collection and preservation, the sensitivity of the detection technique, the anatomic site sampled, and geographic demographics. 1 Indeed, Belgium presents with a higher incidence of HNSCC associated with smoking and alcohol consumption compared with other countries. Moreover, a large variability in the HPV prevalence has been observed among the various anatomic sites of head and neck cancer. For example, the incidence of HPV infection in laryngeal squamous cell carcinoma ranges from 3% to 85% in the literature. 3, 5, [33] [34] [35] [36] The high incidence of HPV in our samples might also be explained by the fact that a very sensitive PCR (GP5þ/GP6þ primers: 10-100 copies per reaction) was used in combination with a type-specific real-time qPCR analysis and a short amplification product (60-80 bp). This conclusion has also been shared by other researchers. 37 Similarly, Termine et al. 38 demonstrated that PCRbased studies resulted in higher prevalence rates compared with studies using ISH, which is less sensitive. Our results confirmed this finding, as almost 65% of HPVþ specimens were also positive using ISH. We recently demonstrated that 82% of hypopharyngeal carcinomas and 75% of laryngeal carcinomas were infected by hr HPV. 5, 19 The high incidence of HPV infection in our series of hypopharyngeal, laryngeal, and OSCC samples calls into question whether contamination may explain our results. To address this important question, several precautions were taken to prevent tissue contamination. The high frequency of HPV positivity in OSCCs is a strong argument for a potential carcinogenic role of hr HPV serotypes in oral cancer.
It is important to recall that HNSCC is comprised of two distinct clinical entities: HPV-negative tumors, which typically occur in individuals with histories of tobacco and alcohol use, and HPV-positive tumors, which are usually not associated with these risk factors. 39 In the population of patients included in this study, the prevalence of tobacco and alcohol use was very high in both the hr HPV-positive (52 smokers and 44 drinkers) and HPV-negative (32 smokers and 27 drinkers) patients. Moreover, the detection of hr HPV was not found to be significantly more frequent in patients who reported to be free of these risk factors (7 nonsmokers and 15 nondrinkers). Smith et al. have also shown that there was no distinction between these two risk profiles. 40 Many studies have reported that detection of HPV DNA is closely associated with an improved outcome in patients with HNSCC. 8, 40, 41 However, our results revealed a greater risk of recurrence in patients with HPV-positive samples (P ¼ .007). Notably, the majority of studies that demonstrated increased survival were reporting on patients with oropharyngeal and/or tonsillar tumors. [42] [43] [44] The meta-analysis by Ragin and Taioli examining the relationship between HPV and overall survival did not show any survival differences between HPVþ and HPVÀ patients with cancers at nonoropharyngeal sites. 41 The same observation was made by Gillison et al., suggesting that these tumors may have an etiology distinct from tumors at nonoropharyngeal sites. 39 The poor prognosis reported in the hr HPVþ population in this study has been demonstrated in other studies. Indeed, two Swedish studies demonstrated that oral HPV infection was associated with a dramatically increased risk of OSCC development. 7, 45 In addition, Clayman et al. 46 showed that HPV detection was significantly correlated with decreased survival. Other studies have failed to demonstrate an association between HPV positivity and prognosis. 5, 19, 47 We hypothesize that immunosuppression might favor HPV infection. 48 In 2004, Kreimer et al. 49 reported that tonsillar HPV infection was strongly associated with HIV coinfection and immunosuppression. Recently, herpes simplex virus-2 infection was demonstrated to increase the risk of HPV infection. 50 A study performed by Tung et al. reported the presence of HPV 16 or 18 and Epstein Barr virus in 80% of nasopharyngeal carcinoma samples. 51 These coinfections might play an important role in the initiation of neoplastic transformation in human oral epithelial cells. HPV infections have also been implicated in several tumor cell immune escape mechanisms, such as the absence of an inflammatory response against tumor cells, the production of regulatory cytokines, and the downregulation of Toll-like receptor 9. 52 During malignant transformation, the early HPV proteins E6 and E7 interact with tumor suppressor genes, promoting their degradation. 5 The p16 tumor suppressor gene is frequently upregulated in HPVþ HNSCC because p16 is negatively regulated by pRb. This upregulation is described in numerous studies qualifying p16 as a marker of positivity for HPV infection. However, although the role of p16 is clear for nondrinking/nonsmoking patients, this association is not confirmed for smoking/drinking patients (as observed in our clinical series). Indeed, Begum et al. have shown that p16 overexpression is a marker of oropharyngeal origin and has an association with HPV infection in HNSCC tumors. 53 In contrast, in tobacco-related HNSCCs, the loss of the tumor-suppressor p16 protein is a common and early event in tumorigenesis. 54 In the OSCC specimens from our study, mainly composed of smoking/drinking patients, we found that the overexpression of p53 and p16 was not associated with the presence of hr HPV serotypes. A study on OSCC cells conducted by Friedrich et al. also demonstrated that p16 expression is not an effective surrogate marker of HPV infection. 30 Immunohistochemical detection of p16 is, however, considered a good marker for HPV-associated carcinogenesis in HNSCC, especially oropharyngeal and tonsillar carcinomas. 21, 55 Although there is some evidence to link HPV infection with molecular alterations in p16 and p53 expression, it must be noted that these observations have been described primarily in cervical carcinoma. Moreover, the lack of immunoreactivity in our samples indicates that the inactivation of tumor suppressor genes is an early and frequent event in oral tumorigenesis. Importantly, Fury et al. reported a significant association between a history of tobacco use and the absence of p16 expression. 56 These results confirm that HPV-positive and HPV-negative tumors are two distinct entities at the molecular level.
CONCLUSION
A strength of this study is that it was performed on a large and homogenous case series of patients with thoroughly detailed histories of tobacco and alcohol use. Using these data, we showed that OSCCs presented a high prevalence (44%) of hr HPV infections and that these infections were correlated with a poorer prognosis (P ¼ .007). We did not find a particular HPV-specific biologic signature by examining p16 and p53 expression, which suggests that the biology of tobacco-associated carcinoma is more complex than that of carcinomas exclusively related to HPV. 
